Suppr超能文献

端粒酶逆转录酶(TERT)启动子突变是甲状腺乳头状癌复发和死亡的主要指标。

TERT promoter mutations are a major indicator of recurrence and death due to papillary thyroid carcinomas.

作者信息

Bullock Martyn, Ren Yan, O'Neill Christine, Gill Anthony, Aniss Adam, Sywak Mark, Sidhu Stan, Delbridge Leigh, Learoyd Diana, de Vathaire Florent, Robinson Bruce G, Clifton-Bligh Roderick J

机构信息

Cancer Genetics Unit, Hormones and Cancer Group, Kolling Institute of Medical Research, Royal North Shore Hospital, Sydney, NSW, Australia.

National Institute of Health and Medical Research (Inserm), Center for research in Epidemiology and Population Health (CESP), U1018, Radiation Epidemiology Group, Villejuif, France.

出版信息

Clin Endocrinol (Oxf). 2016 Aug;85(2):283-90. doi: 10.1111/cen.12999. Epub 2016 Feb 8.

Abstract

CONTEXT

TERT promoter mutations have been associated with adverse prognosis in papillary thyroid carcinomas (PTCs).

OBJECTIVE

We investigated the association between TERT promoter mutations and survival from PTC.

DESIGN

Retrospective observational cohort study.

PATIENTS

Eighty consecutive patients with PTC who underwent surgery between 1990 and 2003.

MEASUREMENTS

TERT promoter was genotyped in DNA from 80 archival PTCs by Sanger sequencing. Median follow-up was 106 months (range 1-270). Outcomes analysis was stratified according to disease and overall survival status. For each parameter, relative risk (RR) adjusted for age at first surgery and gender was estimated. Both univariate and multivariate analyses were performed using logistic regression, Kaplan-Meier survival analysis and Cox regression models.

RESULTS

PTCs from 11 patients (14%) contained either C228T or C250T TERT promoter mutation. TERT mutations were significantly associated with adverse prognostic features such as older age (P = 0·002), male gender (P = 0·01) and Stage IV disease (P = 0·03). Four patients died from PTC during follow-up: 3 patients with TERT mutations (27%) and one without (1·5%). Disease-related mortality rate with or without TERT mutations was 33·7 vs 1·6 per 1000 patient-years respectively, that is 10 (95% CI = 1·0-104·1, P = 0·05) fold higher, after adjustment for age at first surgery and gender. The combination of TERT promoter mutation and BRAF(V) (600E) significantly increased disease-related death risk (P = 0·002). TERT mutations increased expression of a reporter gene in thyroid cells containing BRAF(V) (600E) .

CONCLUSIONS

TERT promoter mutations are a major indicator of death due to PTCs. Conversely, absence of TERT mutations portends better survival.

摘要

背景

端粒酶逆转录酶(TERT)启动子突变与甲状腺乳头状癌(PTC)的不良预后相关。

目的

我们研究了TERT启动子突变与PTC患者生存之间的关联。

设计

回顾性观察队列研究。

患者

1990年至2003年间连续80例接受手术的PTC患者。

测量

通过桑格测序对80例存档PTC的DNA中的TERT启动子进行基因分型。中位随访时间为106个月(范围1 - 270个月)。根据疾病和总体生存状况对结果分析进行分层。对于每个参数,估计了根据首次手术时年龄和性别调整后的相对风险(RR)。使用逻辑回归、Kaplan-Meier生存分析和Cox回归模型进行单变量和多变量分析。

结果

11例患者(14%)的PTC含有C228T或C250T TERT启动子突变。TERT突变与不良预后特征显著相关,如年龄较大(P = 0·002)、男性(P = 0·01)和IV期疾病(P = 0·03)。4例患者在随访期间死于PTC:3例有TERT突变(27%),1例无TERT突变(1·5%)。有或无TERT突变的疾病相关死亡率分别为每1000患者年33·7和1·6,在根据首次手术时年龄和性别调整后,前者是后者的10倍(95%CI = 1·0 - 104·1,P = 0·05)。TERT启动子突变与BRAF(V)(600E)的联合显著增加了疾病相关死亡风险(P = 0·002)。TERT突变增加了含有BRAF(V)(600E)的甲状腺细胞中报告基因的表达。

结论

TERT启动子突变是PTC导致死亡的主要指标。相反,无TERT突变预示着更好的生存。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ccf0/5683578/b2b28a321db6/CEN-85-283-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验